Literature DB >> 30063141

Identification of Natural Compound Radicicol as a Potent FTO Inhibitor.

Ruiyong Wang, Zhifu Han1, Bingjie Liu2, Bin Zhou1, Ning Wang, Qingwei Jiang, Yan Qiao, Chuanjun Song, Jijie Chai1, Junbiao Chang2.   

Abstract

The fat mass and obesity-associated protein (FTO), as an m6A demethylase, is involved in many human diseases. Virtual screening and similarity search in combination with bioactivity assay lead to the identification of the natural compound radicicol as a potent FTO inhibitor, which exhibits a dose-dependent inhibition of FTO demethylation activity with an IC50 value of 16.04 μM. Further ITC experiments show that the binding between radicicol and FTO was mainly entropy-driven. Crystal structure analysis reveals that radicicol adopts an L-shaped conformation in the FTO binding site and occupies the same position as N-CDPCB, a previously identified small molecular inhibitor of FTO. Unexpectedly, however, the 1,3-diol group conserved in radicicol and N-CDPCB assumes strikingly different orientations for interaction with FTO. The identification of radicicol as an FTO inhibitor and revelation of its recognition mechanism not only opens the possibility of developing new therapeutic strategies for treatment of leukemia but also provide clues for elucidation of the acting mechanisms of radicicol, which is a possible clinical candidate worth in-depth study.

Entities:  

Keywords:  FTO; inhibitor; radicicol

Mesh:

Substances:

Year:  2018        PMID: 30063141     DOI: 10.1021/acs.molpharmaceut.8b00522

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  16 in total

1.  Comparative study of the binding between chlorogenic acid and four proteins by isothermal titration calorimetry, spectroscopy and docking methods.

Authors:  Miao Zhang; Ning Zhang; Xinluan Lu; Wenjin Li; Ruiyong Wang; Junbiao Chang
Journal:  Pharmacol Rep       Date:  2022-05-11       Impact factor: 3.024

Review 2.  One Stone, Two Birds: N6-Methyladenosine RNA Modification in Leukemia Stem Cells and the Tumor Immune Microenvironment in Acute Myeloid Leukemia.

Authors:  Xianfeng Ouyang; Yuping Gong
Journal:  Front Immunol       Date:  2022-06-02       Impact factor: 8.786

Review 3.  The Structure Basis of Phytochemicals as Metabolic Signals for Combating Obesity.

Authors:  Xiaoping Li; Liufeng Zheng; Bing Zhang; Ze-Yuan Deng; Ting Luo
Journal:  Front Nutr       Date:  2022-06-13

Review 4.  Nutritional Epigenetics in Cancer.

Authors:  Maria J Barrero; Paloma Cejas; Henry W Long; Ana Ramirez de Molina
Journal:  Adv Nutr       Date:  2022-10-02       Impact factor: 11.567

Review 5.  Multiple Functions and Mechanisms Underlying the Role of METTL3 in Human Cancers.

Authors:  Wenhui Zheng; Xiaoshen Dong; Yan Zhao; Shuo Wang; Haiyang Jiang; Mingdi Zhang; Xinyu Zheng; Ming Gu
Journal:  Front Oncol       Date:  2019-12-12       Impact factor: 6.244

Review 6.  Regulatory Role of the RNA N6-Methyladenosine Modification in Immunoregulatory Cells and Immune-Related Bone Homeostasis Associated With Rheumatoid Arthritis.

Authors:  Danping Fan; Ya Xia; Cheng Lu; Qinbin Ye; Xiaoyu Xi; Qiong Wang; Zheng Wang; Chengyuan Wang; Cheng Xiao
Journal:  Front Cell Dev Biol       Date:  2021-01-21

Review 7.  Structural Insights Into m6A-Erasers: A Step Toward Understanding Molecule Specificity and Potential Antiviral Targeting.

Authors:  Mahmoud Bayoumi; Muhammad Munir
Journal:  Front Cell Dev Biol       Date:  2021-01-12

Review 8.  Emerging role of m6A methylation modification in ovarian cancer.

Authors:  Lin-Lin Chang; Xia-Qing Xu; Xue-Ling Liu; Qian-Qian Guo; Yan-Nan Fan; Bao-Xia He; Wen-Zhou Zhang
Journal:  Cancer Cell Int       Date:  2021-12-11       Impact factor: 5.722

Review 9.  RNA N6-methyladenosine: a promising molecular target in metabolic diseases.

Authors:  Huakui Zhan; Keyang Xu; Yan Li; Jiawen Wang; Chunyan Huang; Meng Shen
Journal:  Cell Biosci       Date:  2020-02-21       Impact factor: 7.133

Review 10.  N6 -methyladenosine (m6A) RNA modification in human cancer.

Authors:  Fu-Chun Huo; Zhi-Man Zhu; Dong-Sheng Pei
Journal:  Cell Prolif       Date:  2020-10-07       Impact factor: 8.755

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.